ZyVersa Therapeutics Analysis
| ZVSADelisted Stock | 0.15 0.01 7.14% |
ZyVersa Therapeutics is overvalued with Real Value of 0.14 and Hype Value of 0.15. The main objective of ZyVersa Therapeutics delisted stock analysis is to determine its intrinsic value, which is an estimate of what ZyVersa Therapeutics is worth, separate from its market price. There are two main types of ZyVersa Therapeutics' stock analysis: fundamental analysis and technical analysis.
The ZyVersa Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and ZyVersa Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
ZyVersa |
ZyVersa Stock Analysis Notes
The company has Price to Book (P/B) ratio of 0.09. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. ZyVersa Therapeutics recorded a loss per share of 4.68. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 26th of April 2024. For more information please call the company at (754) 231-1688 or visit https://www.zyversa.com.ZyVersa Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more delisted stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. ZyVersa Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding ZyVersa Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| ZyVersa Therapeutics generated a negative expected return over the last 90 days | |
| ZyVersa Therapeutics has high historical volatility and very poor performance | |
| ZyVersa Therapeutics has some characteristics of a very speculative penny stock | |
| ZyVersa Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (9.41 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ZyVersa Therapeutics generates negative cash flow from operations | |
| Latest headline from globenewswire.com: ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and RD Progress |
ZyVersa Therapeutics Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ZyVersa Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
ZyVersa Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 707.14 K.Technical Drivers
As of the 24th of July, ZyVersa Therapeutics maintains the Standard Deviation of 10.32, mean deviation of 6.22, and Market Risk Adjusted Performance of (5.47). Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of ZyVersa Therapeutics, as well as the relationship between them.ZyVersa Therapeutics Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. ZyVersa Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for ZyVersa Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
ZyVersa Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ZyVersa Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on ZyVersa Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ZyVersa Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ZyVersa Therapeutics Outstanding Bonds
ZyVersa Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ZyVersa Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ZyVersa bonds can be classified according to their maturity, which is the date when ZyVersa Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US98981BAA08 Corp BondUS98981BAA08 | View | |
| US98980BAA17 Corp BondUS98980BAA17 | View |
ZyVersa Therapeutics Predictive Daily Indicators
ZyVersa Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ZyVersa Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
ZyVersa Therapeutics Forecast Models
ZyVersa Therapeutics' time-series forecasting models are one of many ZyVersa Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ZyVersa Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding ZyVersa Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Piotroski F Score Now
Piotroski F ScoreGet Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
| All Next | Launch Module |
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in ZyVersa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in ZyVersa Stock
If you are still planning to invest in ZyVersa Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ZyVersa Therapeutics' history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |